Royalty Pharma (RPRX) Cash & Current Investments (2020 - 2026)

Royalty Pharma (RPRX) has 7 years of Cash & Current Investments data on file, last reported at $608.3 million in Q1 2026.

• For the quarter ending Q1 2026, Cash & Current Investments fell 44.69% year-over-year to $608.3 million; the trailing twelve-month figure through Mar 2026 stood at $608.3 million (down 44.69% YoY), and the FY2025 full-year result was $637.5 million, down 35.43% from the prior year.
• Cash & Current Investments fell to $608.3 million in Q1 2026, from $637.5 million in the prior quarter.
• In the past five years, Cash & Current Investments ranged from a high of $2.5 billion in Q2 2022 to a low of $495.3 million in Q4 2023.
• A 5-year average of $1.3 billion and a median of $998.6 million in 2024 frame the typical range for Cash & Current Investments.
• Across the five-year window, Cash & Current Investments soared 104.11% in 2022 and sank 71.45% in 2023, its largest moves.
• Tracing RPRX's Cash & Current Investments over 5 years: stood at $1.7 billion in 2022, then plunged by 71.45% to $495.3 million in 2023, then surged by 99.31% to $987.2 million in 2024, then tumbled by 35.43% to $637.5 million in 2025, then declined by 4.58% to $608.3 million in 2026.
• Business Quant data shows RPRX's Cash & Current Investments at $608.3 million in Q1 2026, $637.5 million in Q4 2025, and $955.0 million in Q3 2025.